CRISPRs Enlisted to Study Mutations Across an Entire Mammalian Genome
By GEN,
Genetic Engineering & Biotechnology News
| 12. 24. 2013
Scientists at the Wellcome Trust Sanger Institute have developed a technique to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types, the researchers say.
CRISPR technology uses the DNA-cutting enzyme Cas9, with the help of a guide RNA sequence, to find and modify genetic targets. Scientists engineer multiple new guide RNAs using standard molecular biology techniques. This makes for a much faster and efficient method to modify the genome of any cell type in any species, according to the Wellcome group.
The team, which published their results online (“Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library”) in Nature Biotechnology, found that 50 of 52 guide RNAs tested successfully cut both copies of the genes. The high success rate for these engineered guide RNAs seems to be consistent across many cell types, which led them to create a library of guide RNAs targeting every gene in the mouse genome.
“We designed 87,897 guide RNAs (gRNAs) targeting...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...